Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD
- 31 May 2009
- journal article
- research article
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 53 (5), 741-750
- https://doi.org/10.1053/j.ajkd.2008.11.025
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 27 references indexed in Scilit:
- Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)American Journal of Kidney Diseases, 2008
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart DiseaseClinical Journal of the American Society of Nephrology, 2007
- The exclusion of patients with chronic kidney disease from clinical trials in coronary artery diseaseKidney International, 2006
- Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular DiseaseCirculation, 2006
- Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary DiseaseCirculation, 2005
- Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinicsJournal of the American College of Cardiology, 2004
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Kidney Disease as a Risk Factor for Development of Cardiovascular DiseaseHypertension, 2003
- Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)JAMA, 2002